|
| related topics |
| {property, intellectual, protect} |
| {financial, litigation, operation} |
| {product, candidate, development} |
| {regulation, government, change} |
| {operation, international, foreign} |
| {cost, operation, labor} |
|
|
Abbott may acquire other businesses, license rights to technologies or products, form alliances, or dispose of or spin-off businesses, which could cause it to incur significant expenses and could negatively affect profitability.
The expiration or loss of patent protection and licenses may affect Abbott's future revenues and operating income.
Competitors' intellectual property may prevent Abbott from selling its products or have a material adverse effect on Abbott's future profitability and financial condition.
Abbott is subject to cost-containment efforts that could cause a reduction in future revenues and operating income.
Abbott is subject to numerous governmental regulations and it can be costly to comply with these regulations and to develop compliant products and processes.
Laws and regulations affecting government benefit programs could impose new obligations on Abbott, require Abbott to change its business practices, and restrict its operations in the future.
Abbott's research and development efforts may not succeed in developing commercially successful products and technologies, which may cause Abbott's revenue and profitability to decline.
New products and technological advances by Abbott's competitors may negatively affect Abbott's results of operations.
The manufacture of many of Abbott's products is a highly exacting and complex process, and if Abbott or one of its suppliers encounters problems manufacturing products, Abbott's business could suffer.
Significant safety issues could arise for Abbott's products, which could have a material adverse effect on Abbott's revenues and financial condition.
The international nature of Abbott's business subjects it to additional business risks that may cause its revenue and profitability to decline.
Other factors can have a material adverse effect on Abbott's future profitability and financial condition.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Full 10-K form ▸
|
|
| related documents |
| 1800--2/19/2008--ABBOTT_LABORATORIES |
| 1800--2/23/2007--ABBOTT_LABORATORIES |
| 1800--2/22/2006--ABBOTT_LABORATORIES |
| 880432--9/28/2010--MISONIX_INC |
| 875045--2/9/2010--BIOGEN_IDEC_INC. |
| 875045--2/21/2007--BIOGEN_IDEC_INC |
| 875045--2/6/2009--BIOGEN_IDEC_INC. |
| 875045--2/14/2008--BIOGEN_IDEC_INC. |
| 945828--9/15/2008--AMERITYRE_CORP |
| 310158--2/28/2007--SCHERING_PLOUGH_CORP |
| 945828--9/17/2007--AMERITYRE_CORP |
| 945828--9/13/2006--AMERITYRE_CORP |
| 945828--9/28/2010--AMERITYRE_CORP |
| 945828--9/28/2009--AMERITYRE_CORP |
| 1029023--3/17/2008--SYNTROLEUM_CORP |
| 1063254--3/4/2008--S1_CORP_/DE/ |
| 310158--2/28/2006--SCHERING_PLOUGH_CORP |
| 1063254--3/16/2006--S1_CORP_/DE/ |
| 1325279--4/15/2010--CELLCYTE_GENETICS_CORP |
| 64978--2/27/2009--MERCK_&_CO_INC |
| 64978--2/28/2008--MERCK_&_CO_INC |
| 1133421--2/9/2010--NORTHROP_GRUMMAN_CORP_/DE/ |
| 1099800--2/26/2010--Edwards_Lifesciences_Corp |
| 773840--2/12/2010--HONEYWELL_INTERNATIONAL_INC |
| 1101026--4/14/2010--HEALTH_ENHANCEMENT_PRODUCTS_INC |
| 1098880--3/30/2010--IntelGenx_Technologies_Corp. |
| 1098880--3/25/2009--IntelGenx_Technologies_Corp. |
| 708818--6/1/2010--QUALITY_SYSTEMS_INC |
| 76334--8/26/2010--PARKER_HANNIFIN_CORP |
| 102198--10/28/2008--COMPETITIVE_TECHNOLOGIES_INC |
|